Evidence map›Paper›PMID 33382535›Full record

ArticleThe journal of pathology. Clinical research2021

Chromosome 2q gain and epigenetic silencing of GATA3 in microglandular adenosis of the breast.

Martin Radner, Jana Lisa van Luttikhuizen, Stephan Bartels, Janin Bublitz, Isabel Grote, Luisa Rieger, Henriette Christgen, Helge Stark, Christopher Werlein, Marcel Lafos and 4 more

Open access · goldAbstract read
In one paragraph

Article in The journal of pathology. Clinical research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Martin RadnerInstitute of Pathology, Hannover Medical School, Hannover, Germany.ORCID 0000-0001-6913-8380
Jana Lisa van LuttikhuizenDepartment of Human Genetics, Hannover Medical School, Hannover, Germany.
Stephan BartelsInstitute of Pathology, Hannover Medical School, Hannover, Germany.ORCID 0000-0002-8903-2345
Janin BublitzDepartment of Human Genetics, Hannover Medical School, Hannover, Germany.
Isabel GroteInstitute of Pathology, Hannover Medical School, Hannover, Germany.
Luisa RiegerInstitute of Pathology, Hannover Medical School, Hannover, Germany.
Henriette ChristgenInstitute of Pathology, Hannover Medical School, Hannover, Germany.
Helge StarkInstitute of Pathology, Hannover Medical School, Hannover, Germany.ORCID 0000-0002-2668-8056
Christopher WerleinInstitute of Pathology, Hannover Medical School, Hannover, Germany.
Marcel LafosInstitute of Pathology, Hannover Medical School, Hannover, Germany.
Doris SteinemannDepartment of Human Genetics, Hannover Medical School, Hannover, Germany.
Ulrich LehmannInstitute of Pathology, Hannover Medical School, Hannover, Germany.
Matthias ChristgenInstitute of Pathology, Hannover Medical School, Hannover, Germany.
Hans KreipeInstitute of Pathology, Hannover Medical School, Hannover, Germany.
Medizinische Hochschule Hannover · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Microglandular adenosis (MGA) represents a rare neoplasm of the mammary gland, which in a subset of cases may be associated with triple-negative breast cancer (BC). The biology of MGA is poorly understood. In this study, eight MGA cases (n = 4 with and n = 4 without associated BC) were subjected to a comprehensive characterization using immunohistochemistry, genome-wide DNA copy number (CN) profiling, fluorescence in situ hybridization (FISH), next-generation sequencing (NGS), and DNA methylation profiling using 850 K arrays and bisulfite pyrosequencing. Median patient age was 61 years (range 57-76 years). MGA lesions were estrogen receptor (ER)-negative, progesterone receptor-negative, HER2-negative, and S100-positive. DNA CN alterations (CNAs) were complex or limited to few gains and losses. CN gain on chromosome 2q was the most common CNA and was validated by FISH in five of eight cases. NGS demonstrated an average of two mutations per case (range 0-5) affecting 10 different genes (ARID1A, ATM, CTNNB1, FBXW7, FGFR2, MET, PIK3CA, PMS2, PTEN, and TP53). CNAs and mutations were similar in MGA and adjacent BC, indicating clonal relatedness. DNA methylation profiling identified aberrant hypermethylation of CpG sites within GATA3, a key transcription factor required for luminal differentiation. Immunohistochemistry showed regular GATA3 protein expression in the normal mammary epithelium and in ER-positive BC. Conversely, GATA3 was reduced or lost in all MGA cases tested (8/8). In conclusion, MGA is characterized by common CN gain on chromosome 2q and loss of GATA3. Epigenetic inactivation of GATA3 may provide a new clue to the peculiar biology of this rare neoplasia.

Indexed as

Chromosome AberrationsChromosomes, Human, Pair 2DNA MethylationGene SilencingAgedBiomarkers, TumorFemaleFibrocystic Breast DiseaseGATA3 Transcription FactorHumansMiddle AgedMolecular Diagnostic TechniquesPrecancerous ConditionsTriple Negative Breast NeoplasmsBiomarkers, TumorGATA3 protein, humanGATA3 Transcription Factorbreast cancer precursorDNA methylationepigenetic alterationluminal differentiationstem celltriple-negative breast cancer

Identifiers

PMID33382535
PMCPMC8073017
OpenAlexW3116600621

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.